Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms and conditions are excluded:
• •Known hypersensitivity to a component of the vaccine.
• •Evidence of fetal abnormality on ultrasound.
• •Evidence of maternal risk factors including insulin-dependent diabetes, moderate to severe hypertension, repeated fetal wastage (\> 3), Rh-sensitization or other blood group alloimmunization, severe renal disease, previous infants with malformations or other factors that obstetrically are judged to constitute a special risk of spontaneous abortion or premature birth.
• •Active syphilis.
• •Hepatitis B surface antigen positive.
• •Concurrent Medication:
• •Excluded:
• •Antiretroviral or immunomodulating agent other than AZT during the pregnancy.
• •Prior Medication:
• •Excluded:
• •Antiretroviral or immunomodulating agent other than AZT within 90 days prior to study entry.
• •Current use of illicit drugs or known chronic alcohol use.